Interim Report January - March 2001

Interim report 1 January - 31 March 2002 q Strategically important agreement Three-year partnership agreement with Oxford GlycoSciences plc for the joint development of antibody-based drugs. q Expanded development partnership Agreement with GlaxoSmithKline Biologics S.A. for the delivery of antibodies from the n-CoDeR(TM) antibody library. q New antibody library. BioInvent launched n-CoDeR-in Fab format, a new antibody library, and has thereby diversified the company's offering to customers. q Net revenue for January - March 2002: SEK 18.0 million (11.8). q Loss after net financial items for January - March 2002: SEK - 11.7 million (-11.4). q Cash flow from current operations and investment activity, January - March 2002: SEK 24.4 million. Liquid funds at end of period: SEK 363.1 million. Contact: Questions about this report will be answered by: Svein Mathisen, President and CEO, +46 (0)46 286 85 67 or Jonas Källmén, CFO, +46 (0)46 286 38 12. Financial reports are also available at: www.bioinvent.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00570/wkr0002.doc The full report http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00570/wkr0003.pdf The full report